Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YCT-529 in healthy male subjects
NCT06094283Phase 1Completed
- Sponsor
- YourChoice Therapeutics
- Start
- Dec 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in male contraception comparing YCT-529 with Placebo (2 arms). Primary endpoints: Incidence and nature of adverse events, Vital signs assessment (heart rate) and 11 more. Started Dec 2023; status: completed.
02
Drugs
YCT-529
03
Conditions
male contraception
Beyond the preview
Go deeper on NCT06094283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094283.